Molecular detection of TP53, Ki-Ras and p16INK4A promoter methylation in plasma of patients with colorectal cancer and its association with prognosis. Results of a 3-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study

Bazan, Viviana; Bruno, Loredana; Augello, Claudia; Agnese, Valentina; Calò, Valentina; Corsale, S; Gargano, G; Terrasi, Marianna; Schirò, Valentina; Fede, Gaetana Di; Adamo, Vincenzo; Intrivici, Chiara; Crosta, A; Rinaldi, Gaetana; Latteri, Federica; Dardanoni, Gabriella; Grassi, Nello; Valerio, Maria Rosaria; Colucci, Giuseppe; Macaluso, Marcella; Russo, Antonio

doi:10.1093/annonc/mdl958

Cited by 45 publications

(36 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the study published by Bazan et al, it was shown that the preoperative detection of mutant KRAS and TP53 in the serum of CRC patients undergoing resective surgery, was predictive of disease recurrence [65]. In another study it was detected the amount of circulating tumor DNA in 18 MCRC patients who underwent surgical resection of their metastases and it was observed that the detection of circulating mutant DNA after surgery was highly predictive of disease recurrence [66].…”

Section: Colorectal Cancermentioning

confidence: 98%

See 1 more Smart Citation

Monitoring tumor-derived cell-free DNA in patients with solid tumors: Clinical perspectives and research opportunities

Espósito¹,

Bardelli²,

Criscitiello³

et al. 2014

Cancer Treatment Reviews

104

View full text Add to dashboard Cite

Circulating cell-free DNA represents a non-invasive biomarker, as it can be isolated from human plasma, serum and other body fluids. Circulating tumor DNA shed from primary and metastatic cancers may allow the non-invasive analysis of the evolution of tumor genomes during treatment and disease progression through 'liquid biopsies'. The serial monitoring of tumor genotypes, which are instable and prone to changes under selection pressure, is becoming increasingly possible. The "liquid biopsy" provide novel biological insights into the process of metastasis and may elucidate signaling pathways involved in cell invasiveness and metastatic competence. This review will focus on the clinical utility of circulating cell free DNA in main solid tumors, including genetic and epigenetic alterations that can be detected.

show abstract

Section: Colorectal Cancermentioning

confidence: 98%

“…This is partly due to KRASmutation, which is currently assessed in the primary tumor. Many studies assessed mutation status in circulating tumor DNA, with the aim to improve patient selection [65], [66], [67] and [68].…”

Section: Colorectal Cancermentioning

confidence: 99%

Monitoring tumor-derived cell-free DNA in patients with solid tumors: Clinical perspectives and research opportunities

Espósito¹,

Bardelli²,

Criscitiello³

et al. 2014

Cancer Treatment Reviews

104

View full text Add to dashboard Cite

show abstract

“…Detection of mutant KRAS in the blood before surgery predicted recurrence (p < 0.01), but not overall survival. 80 Large prospective trials are needed to confirm the prognosis value of ctDNA. Future studies evaluating post-operative ctDNA levels could generate personalized markers based on the unique mutational profile of resected tumors, offering exquisitely high specificity to predict recurrence and/or evaluate prognosis.…”

Section: Cancer Diagnosis and Screeningmentioning

confidence: 99%

Future perspectives of circulating tumor DNA in colorectal cancer

et al. 2017

View full text Add to dashboard Cite

Tumor biopsy is currently the gold standard for diagnosis and in determining cell signaling pathways involved in the development of treatment resistance. However, there are major challenges with this technique, including the need for serial sampling to monitor treatment resistance, which is invasive and also has the potential for selection bias due to intra-tumoral and inter-tumoral heterogeneity. These challenges highlight the need for more effective methods for obtaining Tumor samples. Liquid biopsy analyzes genetic material or tumor cells shed into the blood from the primary tumor and metastatic sites and consequently provides a comprehensive, real-time picture of the tumor burden in an individual patient. Indeed, liquid biopsy has the potential to revolutionize cancer management. Here, we review recent studies on the potential clinical applications of liquid biopsy using circulating tumor DNA in colorectal cancer, including screening, diagnosis, detection of minimal residual disease after surgery, detection of recurrence, prognosis, predicting treatment response, monitoring tumor burden or response during treatment, and tracking resistance. We also discuss recent data demonstrating the utility of detecting KRAS-mutated circulating tumor DNA, both at diagnosis to determine an appropriate treatment strategy and during anti-epidermal growth factor receptor therapy to predict treatment resistance. The future integration of liquid biopsy into clinical practice is discussed, together with alternative approaches and key questions that need to be answered in future clinical studies before this technology can be implemented and used routinely.

show abstract

“…[12][13][14] Ki-ras mutations are associated with significantly worse prognosis for the patient. [14][15][16] Likewise, c-Ha-ras encodes the p21c-Ha-ras protein, which induces G 1 cell cycle phase arrest, 17 and c-Ha-ras hypomethylation is detected in gastric carcinomas, though without affecting the histopathologic appearance of the cancers. 18 Finally, increased serum levels of the ERBB2 protein, which is involved in the signal transduction pathways leading to cell growth and differentiation, are common in patients with gastric carcinomas.…”

Section: Mutations and Oncogenesmentioning

confidence: 99%

Review of the molecular profile and modern prognostic markers for gastric lymphoma: How do they affect clinical practice?

et al. 2012

View full text Add to dashboard Cite

Molecular detection of TP53, Ki-Ras and p16INK4A promoter methylation in plasma of patients with colorectal cancer and its association with prognosis. Results of a 3-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study

Abstract: Detection of Ki-Ras and TP53 mutation in plasma should be significantly related to disease recurrence. These data suggest that patients with a high risk of recurrence can be identified by means of the analysis of tumor-derived plasma DNA with the use of fairly non-invasive techniques.

Cited by 45 publications

References 11 publications

Monitoring tumor-derived cell-free DNA in patients with solid tumors: Clinical perspectives and research opportunities

Monitoring tumor-derived cell-free DNA in patients with solid tumors: Clinical perspectives and research opportunities

Future perspectives of circulating tumor DNA in colorectal cancer

Review of the molecular profile and modern prognostic markers for gastric lymphoma: How do they affect clinical practice?

Contact Info

Product

Resources

About